The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders

Klausen, Mette K.; Thomsen, Morgane; Wörtwein, Gitta; Fink-Jensen, Anders

doi:10.1111/bph.15677

Cited by 91 publications

(49 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several butyrogenic microbial species can naturally enhance GLP-1 levels and brain GLP-1R expression to positively affect dopamine concentration and improve neurobehavioral deficits. Recent work on the potential use of synthetic GLP-1 agonists as a treatment for drug addiction [ 76 , 77 ] further highlights the importance of microbiota in the regulation of dopamine functions in health and disease via the GLP-1 system.…”

Section: Microbiota-gut-brain Axismentioning

confidence: 99%

Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling

et al. 2022

View full text Add to dashboard Cite

Dopamine is a neurotransmitter that plays a critical role both peripherally and centrally in vital functions such as cognition, reward, satiety, voluntary motor movements, pleasure, and motivation. Optimal dopamine bioavailability is essential for normal brain functioning and protection against the development of neurological diseases. Emerging evidence shows that gut microbiota have significant roles in maintaining adequate concentrations of dopamine via intricate, bidirectional communication known as the microbiota-gut-brain axis. The vagus nerve, immune system, hypothalamus–pituitary–adrenal axis, and microbial metabolites serve as important mediators of the reciprocal microbiota-gut-brain signaling. Furthermore, gut microbiota contain intrinsic enzymatic activity that is highly involved in dopamine metabolism, facilitating dopamine synthesis as well as its metabolite breakdown. This review examines the relationship between key genera of gut microbiota such as Prevotella, Bacteroides, Lactobacillus, Bifidobacterium, Clostridium, Enterococcus, and Ruminococcus and their effects on dopamine. The effects of gut dysbiosis on dopamine bioavailability and the subsequent impact on dopamine-related pathological conditions such as Parkinson’s disease are also discussed. Understanding the role of gut microbiota in modulating dopamine activity and bioavailability both in the periphery and in the central nervous system can help identify new therapeutic targets as well as optimize available methods to prevent, delay, or restore dopaminergic deficits in neurologic and metabolic disorders.

show abstract

Section: Microbiota-gut-brain Axismentioning

confidence: 99%

Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Alcohol dependence leads to decreased quality of life for patients and their relatives and presents a considerable burden to society ( Carvalho et al, 2019 ; Klausen et al, 2022 ). Alcohol dependence and alcohol abuse used to be separate disorders in the Diagnostic and Statistical Manual of mental disorders (DSM-IV), whereas, in DSM-V, they are integrated into one broader category of alcohol use disorder (AUD) which includes sub-classifications, depending on the severity of the symptoms ( Kathryn Mchugh and Weiss, 2019 ; Nutt et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide, also known as gastric inhibitory polypeptide (GIP), are endogenous gut-brain peptides that function both as a hormone and neuropeptide and are released from intestinal L-cells and K-cells, respectively, in response to food intake in humans and mice ( Adner and Nygren, 1992 ; Dalgaard et al, 2004 ; Alvarez et al, 2005 ; Pannacciulli et al, 2007 ; Seino et al, 2010 ; Seino and Yabe, 2013 ; Abraham et al, 2015 ; Jerlhag, 2020 ; Marty et al, 2020 ; Eren-Yazicioglu et al, 2021 ). They stimulate glucose-induced insulin secretion, inhibit glucagon secretion, and decrease appetite in humans and mice ( Adner and Nygren, 1992 ; Dalgaard et al, 2004 ; Seino et al, 2010 ; Underwood et al, 2010 ; Seino and Yabe, 2013 ; Abraham et al, 2015 ; Klausen et al, 2022 ). They have the ability to travel across the blood-brain barrier and access the nervous system in humans and rats ( Isbil-Buyukcoskun et al, 2009 ; Eren-Yazicioglu et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…It can also modulate dopamine levels and glutamatergic neurotransmission, which results in behavioral changes in rats, and mice ( Alhadeff et al, 2012 ; Reddy et al, 2016 ; Eren-Yazicioglu et al, 2021 ). Also, it displayed neuroprotective effects in male rats, mice, non-human primates ( Klausen et al, 2022 ) and humans ( Erbil et al, 2019 ). Furthermore, both preclinical and clinical studies indicated the crucial role of GLP-1R in reward function and addictive disorders, including alcohol-seeking and AUD ( Egecioglu et al, 2013 ; Suchankova et al, 2015 ; Jayaram-Lindström et al, 2016 ; Marty et al, 2020 ; Eren-Yazicioglu et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study

Tsermpini

Goričar

Plesničar

et al. 2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Alcohol dependence is a chronic mental disorder that leads to decreased quality of life for patients and their relatives and presents a considerable burden to society. Incretin hormones, such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are endogenous gut-brain peptides, which can travel across the blood-brain barrier and access the nervous system. Their respective receptors, GIPR and GLP-1R, are expressed in the reward-related brain areas and are involved in memory formation and neurogenesis, which results in behavioral changes in rodent models. The current study investigated the potential association of genetic variability of incretin receptors with alcohol dependence and alcohol-related psychosymptomatology. Alcohol dependence and comorbid psychosymptomatology were assessed in a cohort of Slovenian male participants, comprised of 89 hospitalized alcohol-dependent patients, 98 abstinent alcohol-dependent patients, and 93 healthy blood donors. All participants were genotyped for GIPR rs1800437 and GLP1R rs10305420 and rs6923761 polymorphisms. For the statistical analysis Kruskal–Wall and Mann–Whitney tests were used in additive and dominant genetic models. Our findings indicated that GIPR rs1800437 genotypes were associated with an increased risk of alcohol dependence. Statistically significant association between GIPR rs1800437 GG genotype and Brief Social Phobia Scale scores were observed in the abstinent alcohol-dependent patients, while GLP1R rs6923761 GG genotype was associated with Zung anxiety scores in healthy controls. Our pilot study indicates that GIPR rs1800437 may play some role in susceptibility to alcohol dependence, as well as in alcohol-related psychosymptomatology symptoms. To our knowledge, this is the first study that indicates the involvement of GIPR in alcohol dependence. However, studies with larger cohorts are needed to confirm these preliminary findings.

show abstract

“…Furthermore, a reduction in the reward value of food after GLP-1 administration hints at the potential use of GLP-1 in the treatment of addiction, not only to food but also substances of abuse, more generally. This fascinating area of research is reviewed by Klausen et al (2021).…”

mentioning

confidence: 99%

New developments in the prospects for GLP‐1 therapy

Trapp

Stanford

2022

British J Pharmacology

View full text Add to dashboard Cite

The glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, has recently been confirmed as the most efficacious weight-loss drug in clinical use (Wilding et al., 2021), which highlights a major success in the clinical exploitation of the humble 30 amino acid incretin hormone, GLP-1.An incretin is a hormone, produced by the digestive system, that promotes the lowering of the concentration of glucose in the plasma by stimulating the secretion of pancreatic hormones, particularly insulin. The incretin effect describes the more effective stimulation of insulin release following oral ingestion of glucose, by comparison with that induced by infusion of glucose directly into the bloodstream.

show abstract

The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders

Cited by 91 publications

References 148 publications

Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling

Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling

Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study

New developments in the prospects for GLP‐1 therapy

Contact Info

Product

Resources

About